Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.
| Rapid Review Process | Complete |
| Rapid review received | 04/09/2017 |
| Rapid review completed | 19/09/2017 |
| Rapid Review outcome | Full pharmacoeconomic assessment recommended |
| Full pharmacoeconomic assessment commissioned by the HSE | 25/09/2017 |
| Pre-submission consultation with applicant | 23/10/2017 |
| Submission received from applicant | 07/02/2018 |
| Preliminary review part I sent to applicant | 25/04/2018 |
| Preliminary review part II sent to applicant | 23/05/2018 |
| Applicant response to preliminary review part I | 25/05/2018 |
| Applicant response to preliminary review part II | 14/06/2018 |
| NCPE assessment re-commenced | 15/06/2018 |
| Current status | NCPE Assessment ongoing |